[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593815":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":66,"id":70,"slug":17,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":17,"enrollmentInfo":78,"targetDuration":17,"studyType":81,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":50,"whyStopped":17,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Hackensack Meridian Health","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"To evaluate the effectiveness of PSMA-PET scan in identifying recurrent prostate cancer after focal therapy","All patients will get a biopsy to assess the effectiveness of treatment at 1 year, which is standard protocol at our institutions (all patients undergo biopsy at year 1 and 3 at our institutions). The post-treatment PSMA-PET scan will be correlated to 1-year biopsy results to study the utility of such a scan. Recurrence is defined by a positive PSMA-PET scan and positive biopsy in the area of PET scan tracer uptake at 1 year after SOC focal treatment.","Approximately 1 year after SOC focal therapy.",[14],{"measure":15,"description":16,"timeFrame":12},"To report the sensitivity and specificity in evaluating PSMA-PET scan","Sensitivity and specificity will be reported under the ROC and AUC analysis.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","PSMA is a protein that is highly expressed in prostate cancer cells, making it an excellent specific target for imaging with PET scans that can provide detailed information about the location, extent and aggressiveness of prostate cancer lesions. These scans have proven invaluable for identifying and characterizing prostate cancer, aiding in treatment planning, and Monitoring treatment response. It's true and fully utility in focal therapy for prostate cancer is unknown.",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"18F-rhPSMA-7.3","EXPERIMENTAL","Patients will undergo a PSMA-PET scan at 1 year (+\u002F- 60 days) after treatment with SOC focal therapy using a radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)-targeted PET scan using 18F-rhPSMA-7.3 (Posluma).\n\nThe rhPSMA-targeted PET scan is an FDA-approved PET scan to detect the presence of lesions positive for prostate-specific membrane antigen (PSMA) in men with prostate cancer. 18F-rhPSMA-7.3 (Posluma) injection is a radioactive diagnostic agent that is administered in the form of an intravenous injection.",[31],"Drug: 18F-rhPSMA-7.3",[33],{"type":34,"name":27,"description":35,"armGroupLabels":36,"otherNames":17},"DRUG","Utility of 18F-rhPSMA-7.3 in the diagnosis of prostate cancer after Focal Gland Treatment (SCOUT)",[27],[38],{"name":39,"affiliation":5,"role":40},"Nitin Yerrman, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":17,"email":46},"Oncology Clinical Research Referral Office","CONTACT","551-996-1777","OncologyResearchReferral@hmhn.org",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"John Theurer Cancer Center at Hackensack University Medical Center","RECRUITING","Hackensack","New Jersey","07601","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-74.04347,40.88593,{"lat":60,"lon":59},[63],{"name":43,"role":44,"phone":45,"phoneExt":17,"email":46},{"type":65,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[67],{"name":68,"class":69},"Blue Earth Diagnostics","INDUSTRY","100593815",false,"NCT07011342","Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment","SCOUT","Inclusion Criteria:\n\n* Adult males 18 years or older;\n* Patient must have a pre-treatment MRI;\n* Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment;\n* Intermediate risk disease as defined by American Urology Academy (AUA)\u002FNational Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)\n* Life Expectancy of 10 years or more;\n* Underwent standard template biopsy before treatment with a minimum of 2 cores into the MRI visible lesion if lesion was present;\n* Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol; and\n* Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.\n\nExclusion Criteria:\n\n* Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at identifying factors that affect adults only.\n* Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.","MALE","18 Years",{"count":79,"type":80},70,"ESTIMATED","INTERVENTIONAL",[19],"To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy",[85],"Prostate Cancer",[87],"PSMA-PET","2026-03-20",{"date":90,"type":91},"2026-03-23","ACTUAL",{"date":93,"type":91},"2025-10-01",{"date":95,"type":80},"2028-11",{"name":5,"class":6},1]